Heska Corporation (HSKA) Stock
HSKA is no longer traded. Heska was acquired by Mars on June 9, 2023.
Each HSKA share was exchanged for $119.99 in cash. Prices on this page are historical; the last trade was June 12, 2023 at $119.99.
Heska stock price history
HSKA final trading statistics
- Final close
- $119.99
- Final trading day
- Jun 12, 2023
- Market cap at delisting
- $1.31B
- Shares outstanding
- 10.91M
- Final 52-week range
- $57.83 – $120.03
- Avg. volume (final 3 mo.)
- 347,496
- All-time high (split-adj.)
- $274.20 · Aug 2021
- All-time low (split-adj.)
- $1.65 · Mar 2009
- Return since IPO
- +43.2%
- Beta
- 1.60
- Book value / share
- $38.26
- Price / book
- 3.14
Heska annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $257.31M | -$18.4M | -$1.93 |
| FY2021 | $253.74M | $132.0K | -$0.11 |
| FY2020 | $197.32M | -$14.0M | -$1.18 |
| FY2019 | $122.66M | -$1.1M | -$0.15 |
| FY2018 | $127.45M | $5.8M | $1.39 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Heska Corporation
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.
Heska stock FAQ
What happened to Heska stock?
Heska was acquired by Mars on June 9, 2023. Shareholders received $119.99 in cash for each share. HSKA stock stopped trading on the Nasdaq, with a final close of $119.99 on June 12, 2023.
What did Heska shareholders receive?
Each HSKA share was converted into $119.99 in cash. The deal was valued at about $1.3 billion.
Is HSKA stock still trading?
No. HSKA was delisted from the Nasdaq on June 9, 2023 and no longer trades on a U.S. exchange.
What was the last price of HSKA stock?
HSKA closed at $119.99 on its final trading day, June 12, 2023, for a market value of about $1.31B.
What were Heska's revenue and earnings in its last full fiscal year?
Heska reported revenue of $257.31M and net income of -$18.4M in fiscal 2022, its last full year as a public company.
When did Heska go public?
Heska Corporation stock began trading on June 30, 1997.